A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs TAK 041 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors Takeda
- 09 Mar 2018 Planned number of patients changed from 40 to 72.
- 09 Mar 2018 Planned End Date changed from 4 Feb 2018 to 20 Oct 2018.
- 09 Mar 2018 Planned primary completion date changed from 4 Feb 2018 to 20 Oct 2018.